Healthcare / BiotechnologyParis
$6.95
+0.05 (+0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $972528.00 · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
8.4x
↓EV/EBITDA
11.7x
↓ROE
10.2%
↑Gross Margin
116.0%
↑Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+7.8%
FCF CAGR
—
FCF margin
108.2%
FCF / Net income
2.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.9M · net income $935126.0 · FCF $2.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.9M | $1.9M | $1.7M | $1.5M | $1.5M |
| Net Income | $935126.00 | $935126.00 | $79169.00 | $-402541.00 | $-868287.00 |
| EBITDA | $956452.00 | $956452.00 | $185776.00 | $-637071.00 | $-879656.00 |
| EPS | — | — | 0.07 | -0.36 | -0.80 |
| Gross Margin | 116.0% | 116.0% | 128.0% | 130.9% | 133.6% |
| Operating Margin | 12.2% | 12.2% | -35.6% | -78.6% | -105.5% |
| Net Margin | 48.5% | 48.5% | 4.7% | -26.0% | -56.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.54 | 0.63 | 0.55 |
| Current Ratio | 1.19 | 1.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.1M | $2.1M | $972528.00 | $-2258.00 | $-1574.00 |
| Returns | |||||
| ROE | 10.2% | 10.2% | 1.0% | -5.0% | -10.3% |
| Valuation | |||||
| P/E | 8.37 | 8.37 | 66.86 | — | — |
| EV/EBITDA | 11.67 | 11.67 | 51.88 | — | — |
| P/B | 0.84 | 0.84 | 0.65 | 1.88 | 2.40 |
| Growth & Yield | |||||
| Revenue Growth | 14.6% | 14.6% | 8.6% | 0.7% | — |
| EPS Growth | — | — | 120.2% | 55.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → n/d
Residual
-31.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.